Zacks Investment Research Downgrades BIOLASE (NASDAQ:BIOL) to Hold

Share on StockTwits

Zacks Investment Research downgraded shares of BIOLASE (NASDAQ:BIOL) from a buy rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Biolaw Technology, Inc. is the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets. “

Several other analysts also recently issued reports on the company. Benchmark started coverage on BIOLASE in a research note on Wednesday, June 19th. They issued a speculative buy rating and a $2.00 price target on the stock. Dougherty & Co reissued a buy rating on shares of Iteris in a research note on Tuesday, April 30th.

Shares of BIOLASE stock opened at $1.73 on Wednesday. BIOLASE has a 12 month low of $0.91 and a 12 month high of $2.87. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.11 and a current ratio of 1.91. The business’s fifty day simple moving average is $1.63.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings data on Thursday, May 9th. The medical technology company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.05. BIOLASE had a negative return on equity of 120.91% and a negative net margin of 46.05%. The business had revenue of $10.33 million for the quarter, compared to the consensus estimate of $10.52 million. On average, analysts expect that BIOLASE will post -0.59 EPS for the current year.

In other BIOLASE news, major shareholder Larry N. Feinberg sold 1,000,000 shares of BIOLASE stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $1.50, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.50% of the company’s stock.

About BIOLASE

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on BIOLASE (BIOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Chiasma  Lowered to Hold at Zacks Investment Research
Chiasma Lowered to Hold at Zacks Investment Research
Beyondspring  Upgraded to Buy at Zacks Investment Research
Beyondspring Upgraded to Buy at Zacks Investment Research
Newmark Group  Receives New Coverage from Analysts at Compass Point
Newmark Group Receives New Coverage from Analysts at Compass Point
Zacks Investment Research Downgrades BIOLASE  to Hold
Zacks Investment Research Downgrades BIOLASE to Hold
Aldeyra Therapeutics  Rating Lowered to Sell at Zacks Investment Research
Aldeyra Therapeutics Rating Lowered to Sell at Zacks Investment Research
BidaskClub Lowers Live Oak Bancshares  to Sell
BidaskClub Lowers Live Oak Bancshares to Sell


 
© 2006-2019 Zolmax.